Citicoline (CDP-Choline)

Citicoline — also written as CDP-choline or by its full chemical name, cytidine 5′-diphosphocholine — is a compound your own body makes every day as a normal step in building the membranes that wrap its cells. Sold as a supplement (and, in some countries, as a prescription medicine), it has become popular as a “nootropic,” or brain-support supplement, and it has been studied as a possible aid for stroke recovery, age-related memory complaints, and certain eye diseases. This page explains what citicoline actually is, how it works, and — most importantly — what the human evidence does and does not show. The honest short version is that citicoline is a well-tolerated, high-quality source of choline with modest evidence for age-related memory problems and growing interest in glaucoma, but its largest and most rigorous test — a definitive trial in acute stroke — did not confirm the early hope. Throughout, this article separates solid biochemistry from claims that outrun the data. Nothing here is medical advice, and citicoline is not a proven cure for any disease.

Table of Contents

  1. What Citicoline (CDP-Choline) Is
  2. How Citicoline Works in the Body
  3. Cognition and Memory: An Honest Look
  4. Stroke: The Honest Big Picture
  5. Glaucoma and Vision
  6. How Much People Take
  7. Citicoline vs Alpha-GPC vs Plain Choline
  8. Safety and Tolerability
  9. The Honest Bottom Line
  10. Key Research Papers
  11. Connections
  12. Featured Videos

What Citicoline (CDP-Choline) Is

Citicoline is not a foreign chemical — it is a naturally occurring intermediate, a short-lived molecule your cells produce on the way to making phosphatidylcholine, the principal phospholipid of every cell membrane. In the body’s own assembly line for membranes (the Kennedy pathway, described below), choline is first activated by being joined to a cytidine nucleotide; the result of that step is CDP-choline. So when you take citicoline as a supplement, you are taking a compound your own biochemistry already builds and uses.

The full name, cytidine 5′-diphosphocholine, describes its two-part structure: a choline unit linked through a diphosphate bridge to cytidine (a building block related to the nucleotides of RNA). This two-part nature is central to understanding the molecule. When citicoline is swallowed, it is not absorbed whole. In the gut and liver it is split into its two halves — free choline and free cytidine — which enter the bloodstream separately and are then re-used by the body. There is an important species detail here: in humans, most of the absorbed cytidine is converted to uridine (a closely related nucleoside), so the practical raw materials citicoline delivers to human tissues are best described as choline plus uridine. Both halves are re-combined inside cells to rebuild CDP-choline where and when it is actually needed.

This is why citicoline is often summarized as a delivery system for two useful things at once: a source of choline (raw material for the neurotransmitter acetylcholine and for membrane phospholipids) and a source of cytidine/uridine (raw material that feeds the same membrane-building pathway from the other end). That two-for-one quality is the main biochemical rationale behind citicoline’s use for “brain-membrane support,” and it is the feature that distinguishes it from a plain choline salt.

How Citicoline Works in the Body

Citicoline’s proposed benefits all trace back to what its two halves are used for once they reach the cells.

Supplying choline for acetylcholine

Part of the delivered choline is used to make acetylcholine, one of the brain’s key signaling chemicals, deeply involved in attention, learning, and memory. Because acetylcholine-releasing neurons are among those most affected in aging and in some forms of cognitive decline, supplying extra choline is the traditional rationale for testing citicoline in memory conditions. It is worth stating plainly that having a plausible mechanism is not the same as proving a clinical benefit — a distinction the evidence sections below take seriously.

Rebuilding cell membranes (the Kennedy pathway)

The choline and cytidine/uridine that citicoline provides both feed the CDP-choline (Kennedy) pathway, the main route cells use to synthesize phosphatidylcholine and other membrane phospholipids. In theory, giving a cell both a choline source and a nucleotide source at the same time supports its ability to build and repair membranes — the reasoning behind citicoline’s study in conditions where nerve-cell membranes are under stress, such as after a stroke or in a degenerating optic nerve.

A possible role for dopamine and other systems

Laboratory and animal studies suggest citicoline may also influence dopamine signaling (for example, by supporting dopamine release or its receptors) and may help preserve mitochondrial function and limit certain forms of cell-membrane breakdown. These findings are mechanistic and preclinical; they help explain why researchers keep testing citicoline, but they should not be read as proof of benefit in people.

In short, the working idea is simple and biologically reasonable: citicoline hands cells the choline they need for their chemical messenger and the combined choline-plus-uridine they need for their membranes. Whether that translates into a meaningful clinical effect is exactly what the trials try to answer — and, as the next sections show, the answer varies a great deal by condition.

Cognition and Memory: An Honest Look

Citicoline has been studied for decades as an aid for memory and thinking, especially the kind of decline that comes with aging or with reduced blood flow to the brain. The evidence here is best described as modest and mixed — suggestive of a small benefit in older people with memory complaints, but not uniformly strong.

The most careful summary is a Cochrane systematic review by Fioravanti and Yanagi, which pooled randomized trials of CDP-choline for cognitive and behavioral problems in older adults with chronic brain conditions. It found some evidence of benefit for memory and behavior, but cautioned that the studies were generally short, varied in quality and design, and used inconsistent outcome measures — so the finding is encouraging but not definitive. That mixed picture is the honest headline for the whole area.

Several later studies point the same modest direction. In the Italian IDEALE study (Cotroneo and colleagues), older adults with mild vascular cognitive impairment who took oral citicoline held their cognitive scores steady over about nine months while an untreated comparison group tended to decline — but this was an open-label design without a placebo, which limits how much weight it can carry. Reviews such as those by Gareri and colleagues describe citicoline as an old drug with a reasonable safety record and a plausible role as an adjunct in cognitive impairment, while openly noting the doubts that remain. In stroke survivors specifically, Alvarez-Sabin and colleagues reported that long-term citicoline was associated with better preservation of certain cognitive functions after a first ischemic stroke — again a positive but not conclusive signal.

Evidence in healthy people is thinner still. A randomized, placebo-controlled trial by McGlade and colleagues found improvements in attention and motor speed in healthy adolescent males taking citicoline, but such studies are small and short, and they do not establish that citicoline reliably makes healthy adults smarter or sharper. The fair takeaway: citicoline shows a modest, inconsistent cognitive signal, strongest in older people with existing memory or vascular problems, and it should not be marketed as a guaranteed “brain booster.”

Stroke: The Honest Big Picture

Citicoline’s stroke story is the single most important honesty point on this page, because it is a textbook example of an early promise that a definitive trial did not confirm.

For years, citicoline was one of the most studied “neuroprotective” candidates for acute ischemic stroke — the common type caused by a blocked brain artery. The rationale was appealing: by supplying materials to rebuild damaged nerve-cell membranes, citicoline might limit brain injury and speed recovery. An influential pooled analysis of earlier trials by Dávalos and colleagues (2002) suggested that oral citicoline could modestly increase the odds of a good recovery, and this raised real hope.

That hope was then put to a rigorous test in the ICTUS trial (Dávalos and colleagues, published in The Lancet in 2012) — a large, international, randomized, double-blind, placebo-controlled study of more than 2,000 patients, the definitive trial the field had been waiting for. Its result was clear and disappointing: citicoline did not improve overall recovery compared with placebo. In plain terms, the biggest and best-designed test of citicoline for acute stroke was negative. Later meta-analyses and reviews (for example, by Secades and colleagues in 2016, and critical appraisals such as Overgaard’s and Grieb’s) have wrestled with how to reconcile the earlier positive signals with the negative ICTUS result; the responsible reading is that any benefit, if it exists at all, is not robust enough to have shown up in the trial designed specifically to detect it.

So the honest bottom line for stroke is straightforward: despite early enthusiasm, citicoline is not an established, proven treatment for acute ischemic stroke, and the definitive ICTUS trial found no overall benefit. Anyone presenting citicoline as a confirmed stroke therapy is overstating the evidence.

Glaucoma and Vision

A newer and more promising line of research concerns the eye — specifically glaucoma, a group of diseases in which the optic nerve (the cable of nerve fibers carrying vision from the eye to the brain) is progressively damaged, often in association with elevated eye pressure. Because the optic nerve is essentially brain tissue, the same “support the nerve-cell membrane” logic that motivated the stroke research has been applied here.

Several groups — including Parisi and colleagues and later Roberti and colleagues and Gandolfi and colleagues — have reported that citicoline (given orally or, in some studies, as eye drops) may have a neuroprotective effect in glaucoma, with signs of improved or preserved function of the retinal ganglion cells and visual pathway in some patients. This is genuinely interesting, and it has kept citicoline in active ophthalmology research and even in some clinical use as an add-on.

The evidence here should be described as preliminary and emerging, not settled. Many of the studies are relatively small, of varying design, and measure functional or electrophysiological signals rather than long-term preservation of vision in large randomized trials. Importantly, citicoline is investigated as a possible complement to standard eye-pressure–lowering treatment, not a replacement for it. It is a hopeful area worth watching, but not yet a proven therapy that should change how glaucoma is managed.

How Much People Take

In supplements and studies, citicoline is most commonly used at 250–500 mg per day, often taken as a single dose or split into two. Research trials have gone considerably higher: studies in stroke and in cognitive impairment have used doses up to about 2,000 mg per day, and much of the safety data (below) comes from these higher-dose settings.

Citicoline is sold both as plain citicoline and under a branded, patented form; from the body’s point of view both deliver the same choline-plus-cytidine payload once absorbed. It can be taken with or without food. Because the useful cognitive evidence is concentrated in older adults with existing memory or vascular problems — and because there is no established “requirement” for citicoline the way there is a daily requirement for choline itself — there is no single “correct” dose for healthy people. As with any supplement, more is not automatically better, and anyone with a medical condition or on medication should get individualized advice rather than self-prescribing a high dose.

Citicoline vs Alpha-GPC vs Plain Choline

Citicoline is usually grouped with Alpha-GPC (alpha-glycerophosphocholine) as one of the two “premium” choline supplements, and both are often contrasted with cheaper plain choline salts such as choline bitartrate. A few honest points help sort them out:

The practical, honest summary: citicoline and Alpha-GPC are both high-quality choline sources; citicoline additionally supplies uridine-building material, which is its main theoretical edge, but there is not strong head-to-head trial evidence showing one is clearly better than the other for real-world outcomes. Choosing between them is currently a matter of goals, cost, and tolerance more than proven superiority.

Safety and Tolerability

One of citicoline’s clearest strengths is its excellent tolerability. Across many clinical trials — including studies using high doses in stroke and cognitive impairment — citicoline has been consistently well tolerated, with side effects that are uncommon and usually mild. When they occur, reported effects tend to be minor gastrointestinal complaints (such as nausea or stomach upset), headache, or occasional restlessness. Serious adverse events attributable to citicoline have been rare even at the higher doses used in research.

That said, two honest caveats belong here. First, good long-term safety data are limited: most trials run for weeks to months, so the effects of taking citicoline continuously for many years are not well characterized. Second, data in pregnancy and breastfeeding are lacking, so it is not established as safe in those situations and is best avoided unless a clinician advises otherwise. As always, people taking medications or managing a medical condition should seek individualized advice before adding a supplement. None of this is medical advice.

The Honest Bottom Line

Citicoline (CDP-choline) is a naturally occurring compound and a well-tolerated, high-quality source of choline that also supplies the uridine-building material its cousin supplements do not. For age-related memory complaints and mild cognitive impairment, the evidence points to a modest benefit — real enough to keep researchers interested, but not strong or consistent enough to call it a proven treatment. For the eye, its possible neuroprotective role in glaucoma is a genuinely promising, still-emerging area worth watching, though not yet settled and never a substitute for standard care.

The essential honesty note is about stroke: after years of early promise, the large, definitive ICTUS trial was negative, so the headline hope that citicoline meaningfully improves acute-stroke recovery was not confirmed. Taken together, citicoline is a reasonable, low-risk choline supplement with some modest cognitive evidence and interesting eye-health research — but it is not a miracle nootropic, not a proven stroke therapy, and not a cure for any disease. Shorter and true: a safe, decent choline source with modest, honest evidence and one clearly failed headline claim.

Back to Table of Contents

Key Research Papers

  1. Dávalos A, Alvarez-Sabín J, Castillo J, et al; International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). The Lancet. 2012;380(9839):349–357. — The definitive trial; citicoline showed no overall benefit versus placebo in acute ischemic stroke.
  2. Dávalos A, Castillo J, Alvarez-Sabín J, et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke. 2002;33(12):2850–2857. — The earlier pooled analysis that suggested a modest recovery benefit and fueled the later trials.
  3. Secades JJ, Alvarez-Sabín J, Castillo J, et al. Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. Journal of Stroke and Cerebrovascular Diseases. 2016;25(8):1984–1996.
  4. Overgaard K. The effects of citicoline on acute ischemic stroke: a review. Journal of Stroke and Cerebrovascular Diseases. 2014;23(7):1764–1769.
  5. Grieb P. Neuroprotective properties of citicoline: facts, doubts and unresolved issues. CNS Drugs. 2014;28(3):185–193. — A candid appraisal of what is and is not established.
  6. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database of Systematic Reviews. 2005;(2):CD000269. — Encouraging but not definitive evidence for memory and behavior.
  7. Alvarez-Sabín J, Ortega G, Jacas C, et al. Long-term treatment with citicoline may improve poststroke vascular cognitive impairment. Cerebrovascular Diseases. 2013;35(2):146–154.
  8. Cotroneo AM, Castagna A, Putignano S, et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clinical Interventions in Aging. 2013;8:131–137. — Open-label (no placebo); cognition held steady on citicoline.
  9. Gareri P, Castagna A, Cotroneo AM, et al. The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives. Clinical Interventions in Aging. 2015;10:1421–1429.
  10. McGlade E, Agoston AM, DiMuzio J, et al. The effect of citicoline supplementation on motor speed and attention in adolescent males. Journal of Attention Disorders. 2019;23(2):121–134. — Small randomized trial in healthy youths.
  11. Synoradzki K, Grieb P. Citicoline: a superior form of choline? Nutrients. 2019;11(7):1569. — Lays out the choline-plus-cytidine rationale versus other choline forms.
  12. Roberti G, Tanga L, Michelessi M, et al. Cytidine 5′-diphosphocholine (citicoline) in glaucoma: rationale of its use, current evidence and future perspectives. International Journal of Molecular Sciences. 2015;16(12):28401–28417.
  13. Gandolfi S, Marchini G, Caporossi A, et al. Cytidine 5′-diphosphocholine (citicoline): evidence for a neuroprotective role in glaucoma. Nutrients. 2020;12(3):793.
  14. Parisi V, Coppola G, Centofanti M, et al. Evidence of the neuroprotective role of citicoline in glaucoma patients. Progress in Brain Research. 2008;173:541–554.
  15. Jasielski P, Piędel F, Piwek M, et al. Application of citicoline in neurological disorders: a systematic review. Nutrients. 2020;12(10):3113.
  16. Secades JJ. Citicoline: pharmacological and clinical review (updated editions). Revista de Neurología. PubMed: Secades citicoline pharmacological and clinical review. — The long-running comprehensive pharmacology reviews of citicoline.

Back to Table of Contents

Connections

Back to Table of Contents